Treats moderate to severe vasomotor symptoms associated with the menopause. ANDA 90920, held by Am Regent. Estradiol Valerate.
As of Nov 16, 2026, ANDA 90920 (Estradiol Valerate), held by Am Regent, was first approved by FDA on Jan 19, 2010, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Estradiol Valerate Injection is indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 19, 2010 | Original application | Approved | None posted |
| Estradiol Valerate20MG/ML · injectable;injection | Estradiol Valerate | Rx |
| Estradiol Valerate40MG/ML · injectable;injection | Estradiol Valerate | Rx |
| Jun 24, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 24, 2025 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jan 19, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters